Jazz Up Despite Q2 Loss

August 11, 2010 · Filed Under Uncategorized 

Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) was up $0.88 (9.31%) today to $10.33 following a Q2 loss of $6.4 million due to a debt extinguishment.  The company also raised its expected 2010 EPS to between 32 cents and 41 cents per share from the previous expected earnings of between 26 and 41 cents.

Jazz Pharmaceuticals, Inc. is a biopharma company that develops and sells products for neurology and psychiatry.  The company’s products include Xyrem, used to treat excessive daytime sleepiness, and Luvox CR, used to treat obsessive compulsive disorder and social anxiety disorder.

-Michael B. Sauter

Comments

Leave a Reply




    Subscribe to BioHealth Investor BioHealth Investor RSS Feed